Tissue Bank:

TP53 somatic evolution in the normal endometrium of Black and White individuals. DOI: 10.1016/j.ygyno.2025.04.002

Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series. DOI: 10.3390/curroncol32100585

CHANCES: No Publications for this study yet

Clinical Trials:

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. DOI: 10.1016/j.ejca.2025.115584

Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results. DOI: 10.1016/j.ejca.2025.115587

Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics: A Cluster Randomized Clinical Trial. DOI: 10.1001/jamanetworkopen.2025.0185

Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study. DOI: 10.1016/j.gim.2024.101307

Advancing equity in cancer research through principled partnership: stakeholder engagement practices in The Social Interventions for Support during Treatment for Endometrial cancer and Recurrence (SISTER) Study. DOI: 10.1186/s40900-025-00760-w

Other:

Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. DOI: 10.1016/j.ccell.2025.07.005

Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions. DOI: 10.1038/s41467-025-61283-2

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity. DOI: 10.1186/s40164-025-00681-0

Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. DOI: 10.1093/nar/gkaf990

Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing. DOI: 10.1186/s12875-025-03137-w

Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution. DOI: 10.1016/j.ajog.2025.10.044

Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals. DOI: 10.1200/GO-24-00636

Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study. DOI: 10.1016/j.ajog.2025.06.024

Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access. DOI: 10.1093/jnci/djae338

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models. DOI: 10.1002/ctm2.70274

Tissue Bank:

Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations. DOI: 10.1016/j.ygyno.2024.07.690

TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations. DOI: 10.1038/s41388-024-03089-y

Identification of fallopian tube microbiota and its association with ovarian cancer. DOI: 10.7554/eLife.89830

CHANCES: No Publications for this study yet

Clinical Trials:

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib. DOI: 10.1016/j.ygyno.2024.05.002

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. DOI: 10.1038/s41467-024-47215-6

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. DOI: 10.1038/s41416-023-02534-1

NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. DOI: 10.1002/cncr.35151

Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study. DOI: 10.1016/j.gim.2024.101307

Other:

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription Replication Conflicts. DOI: 10.1158/0008-5472.CAN-23-3239

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. DOI: 10.1186/s12943-024-02048-1

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. DOI: 10.6004/jnccn.2023.7331

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. DOI: 10.1186/s12943-024-02125-5

The role of aberrant DNA methylation in cancer initiation and clinical impacts. DOI: 10.1177/17588359231220511

A full list of publications from Dr. Swisher and the Swisher lab can be found here:
elizabeth swisher - Search Results - PubMed